📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Gufic Bio Q3 Net Profit Declines 35% YoY to ₹12.4 Cr; Revenue Up 11% YoY
Gufic Biosciences reported a consolidated revenue of ₹231.4 crore for Q3 FY26, marking an 11.3% growth compared to the same quarter last year. However, net profit for the quarter fell sharply by 35.6% YoY to ₹12.4 crore, down from ₹19.3 crore in Q3 FY25. The profitability was primarily impacted by a significant rise in finance costs, which nearly doubled for the nine-month period to ₹27.2 crore. Additionally, the company announced a small strategic investment of up to USD 50,000 in Selvax Pty Ltd to acquire 3,78,350 ordinary shares.
Key Highlights
Consolidated Revenue for Q3 FY26 stood at ₹231.4 crore, up 11.3% YoY but down 2.4% QoQ.
Consolidated Net Profit for the quarter was ₹12.4 crore, a 35.6% decline from ₹19.3 crore in Q3 FY25.
Finance costs for the nine-month period ended Dec 2025 surged to ₹27.2 crore from ₹14.7 crore YoY.
9M FY26 Basic EPS dropped to ₹4.22 compared to ₹6.18 in 9M FY25.
Board approved further investment in Selvax Pty Ltd at AUD 20 cents per share, totaling up to USD 50,000.
💼 Action for Investors
Investors should exercise caution as the company is facing significant margin pressure from rising interest and depreciation costs despite steady revenue growth. It is important to monitor the company's debt-servicing capability and the performance of its international subsidiaries.
Gufic Biosciences Targets 30% Indore Plant Utilization and EBITDA Breakeven in FY26
Gufic Biosciences has operationalized its advanced Indore facility as of October 2024, which features a monthly capacity of 5 million lyophilized vials and 6 million liquid vials. The company has already secured 203 product approvals for this facility and completed tech transfers for 40 products. Management expects the Indore unit to achieve EBITDA breakeven in FY26 at 30% utilization and become margin accretive by FY27. The strategic focus remains on high-growth platforms including Critical Care, Women's Health (IVF), and Botulinum Toxin (Aesthetics).
Key Highlights
Indore facility monthly capacity includes 5 million lyophilized vials, 6 million liquid vials, and 10 million ampoules.
Targeting 30% capacity utilization and EBITDA breakeven for the Indore facility during FY26.
Received 203 product approvals from State FDA for the Indore unit with more in the pipeline.
EU GMP and UK MHRA regulatory clearances for the new facility are targeted for Q1-FY27.
Strong growth in specialized brands like Guficin Alpha in the Reproductive Immunology segment.
💼 Action for Investors
Investors should track the quarterly utilization rates of the Indore facility and the progress of EU GMP/UK MHRA audits in early FY27 as these are key catalysts for export growth. The company's transition from a pure-play manufacturer to a specialized platform provider in aesthetics and IVF offers potential for long-term margin expansion.
Gufic Bio Q3 Results: Revenue up 11% YoY to ₹231 Cr, PAT drops 35% to ₹12.4 Cr
Gufic Biosciences reported a mixed performance for Q3 FY26, with consolidated revenue growing 11.3% YoY to ₹231.41 crore. However, the bottom line was significantly impacted, with consolidated net profit falling 35.6% YoY to ₹12.42 crore, primarily due to a sharp rise in finance costs and depreciation. For the nine-month period ending December 2025, PAT stands at ₹42.32 crore, down from ₹61.93 crore in the previous year. Additionally, the company approved a small strategic investment of up to USD 50,000 in Australia-based Selvax Pty Ltd.
Key Highlights
Consolidated Revenue from operations increased 11.3% YoY to ₹231.41 crore in Q3 FY26.
Consolidated Net Profit declined by 35.6% YoY to ₹12.42 crore from ₹19.31 crore.
Finance costs surged 70% YoY to ₹8.36 crore, while depreciation expenses rose 66% to ₹7.69 crore.
9-month FY26 consolidated PAT fell to ₹42.32 crore compared to ₹61.93 crore in 9M FY25.
Board approved further investment in Selvax Pty Ltd, Australia, for 3,78,350 shares at AUD 0.20 each.
💼 Action for Investors
Investors should be cautious as rising interest and depreciation costs are significantly eroding profitability despite steady revenue growth. Monitor the company's debt levels and the commissioning of new projects that might be driving these higher expenses.
Gufic Bio Q3 Results: Revenue Up 11% YoY to ₹231 Cr, Net Profit Drops 35% to ₹12.4 Cr
Gufic Biosciences reported a mixed performance for Q3 FY26, with consolidated revenue growing 11.4% year-on-year to ₹231.41 crore. However, net profit saw a sharp decline of 35.6% YoY, falling to ₹12.42 crore from ₹19.31 crore in the previous year's quarter. This bottom-line pressure was primarily driven by a significant rise in finance costs and depreciation expenses. Additionally, the company announced a small strategic investment of up to USD 50,000 in Australia-based Selvax Pty Ltd.
Key Highlights
Consolidated revenue from operations increased 11.4% YoY to ₹231.41 crore.
Net profit declined 35.6% YoY to ₹12.42 crore, with EPS falling from ₹1.93 to ₹1.24.
Finance costs surged by 70% YoY to ₹8.36 crore, impacting overall margins.
Depreciation and amortization expenses rose to ₹7.69 crore from ₹4.62 crore in the year-ago period.
Board approved a further investment of USD 50,000 in Selvax Pty Ltd for 3,78,350 ordinary shares.
💼 Action for Investors
Investors should remain cautious as the company is experiencing significant margin compression due to rising interest and depreciation costs despite steady revenue growth. It is important to monitor if the current capital expenditure leads to better operational efficiencies in the coming quarters.